AU5915100A - Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies - Google Patents

Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies

Info

Publication number
AU5915100A
AU5915100A AU59151/00A AU5915100A AU5915100A AU 5915100 A AU5915100 A AU 5915100A AU 59151/00 A AU59151/00 A AU 59151/00A AU 5915100 A AU5915100 A AU 5915100A AU 5915100 A AU5915100 A AU 5915100A
Authority
AU
Australia
Prior art keywords
glycation
albumin
treatment
prevent
related pathologies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59151/00A
Other languages
English (en)
Inventor
Margo Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exocell Inc
Original Assignee
Exocell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exocell Inc filed Critical Exocell Inc
Publication of AU5915100A publication Critical patent/AU5915100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
AU59151/00A 1999-07-08 2000-07-06 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies Abandoned AU5915100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/349,853 US6355680B1 (en) 1996-02-20 1999-07-08 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
US09349853 1999-07-08
PCT/US2000/018449 WO2001003684A2 (en) 1999-07-08 2000-07-06 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies

Publications (1)

Publication Number Publication Date
AU5915100A true AU5915100A (en) 2001-01-30

Family

ID=23374238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59151/00A Abandoned AU5915100A (en) 1999-07-08 2000-07-06 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies

Country Status (9)

Country Link
US (2) US6355680B1 (US20010034359A1-20011025-C00009.png)
EP (1) EP1242069B1 (US20010034359A1-20011025-C00009.png)
JP (1) JP4833468B2 (US20010034359A1-20011025-C00009.png)
KR (2) KR100817443B1 (US20010034359A1-20011025-C00009.png)
AT (1) ATE298568T1 (US20010034359A1-20011025-C00009.png)
AU (1) AU5915100A (US20010034359A1-20011025-C00009.png)
CA (1) CA2378456C (US20010034359A1-20011025-C00009.png)
DE (1) DE60021113T2 (US20010034359A1-20011025-C00009.png)
WO (1) WO2001003684A2 (US20010034359A1-20011025-C00009.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767724B2 (en) * 2000-02-07 2003-11-20 Novartis Ag Dibenzo (B,F) azepine intermediates

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
CA2420576C (en) * 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
PE20040844A1 (es) * 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
US20080255236A1 (en) * 2007-04-12 2008-10-16 Glycadia, Inc. Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease
CN101868443A (zh) * 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
US20100035993A1 (en) * 2008-08-06 2010-02-11 Cohen Margo P Methods and compositions comprising 2-[(3-chlorophenyl) amino] phenylacetic acid for hyperpermeability and neovascularization disorders of the retina
WO2011090943A1 (en) * 2010-01-22 2011-07-28 Baylor College Of Medicine Removal of pathological albumin from a subject's plasma
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
EP4083029A1 (en) * 2013-08-20 2022-11-02 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
US20170157010A1 (en) * 2015-12-08 2017-06-08 Glycadia, Inc. Methods and compositions for treatment of disorders associated with damage induced by free radicals
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
CN107793323A (zh) * 2017-11-23 2018-03-13 华中科技大学 一种双氯芬酸甲酯的合成方法
CN108047072A (zh) * 2017-11-23 2018-05-18 深圳华中科技大学研究院 一种双氯芬酸钠的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558690A (en) * 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
NL133740C (US20010034359A1-20011025-C00009.png) * 1965-04-08
NO125724B (US20010034359A1-20011025-C00009.png) * 1967-12-20 1972-10-23 Ciba Geigy Ag
US3652762A (en) * 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
NO134946C (US20010034359A1-20011025-C00009.png) * 1970-09-09 1977-01-12 Ciba Geigy Ag
JPS5259131A (en) * 1975-11-10 1977-05-16 Daito Koeki Production of substituted phenyl acetic acids and salts
JPS5283425A (en) * 1975-12-30 1977-07-12 Daito Koeki Production of substituted anilinophenyl acetic acid
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
JPS5920256A (ja) * 1982-07-27 1984-02-01 Hokuriku Seiyaku Co Ltd ２−（２，６−ジフルオロアニリノ）フエニル酢酸誘導体
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
US5021576A (en) * 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
US5518720A (en) * 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US5994401A (en) * 1996-02-20 1999-11-30 Exocell, Inc. In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction
JP2002515031A (ja) * 1996-02-20 2002-05-21 エグゾセル・インコーポレーテッド タンパク質グリコシル化の阻害および血管疾患の予防
JP2003119142A (ja) * 1997-03-31 2003-04-23 Mitsubishi Pharma Corp 糖化蛋白変性物質生成阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767724B2 (en) * 2000-02-07 2003-11-20 Novartis Ag Dibenzo (B,F) azepine intermediates

Also Published As

Publication number Publication date
KR100817443B1 (ko) 2008-03-27
JP2003504328A (ja) 2003-02-04
JP4833468B2 (ja) 2011-12-07
KR20020033725A (ko) 2002-05-07
ATE298568T1 (de) 2005-07-15
DE60021113T2 (de) 2006-06-01
US6355680B1 (en) 2002-03-12
WO2001003684A2 (en) 2001-01-18
EP1242069B1 (en) 2005-06-29
US6552077B2 (en) 2003-04-22
CA2378456C (en) 2012-04-10
KR20070104478A (ko) 2007-10-25
US20010034359A1 (en) 2001-10-25
CA2378456A1 (en) 2001-01-18
DE60021113D1 (de) 2005-08-04
WO2001003684A3 (en) 2002-06-06
EP1242069A2 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
AU5915100A (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
AP1498A (en) Inhibitors of impdh enzyme.
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
WO2004013120A8 (en) Novel benzodioxoles
MX9702865A (es) Agentes estrogenicos.
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
BG101110A (en) Substituted pyrimidine compounds and their application
AU2001272852A1 (en) Composition for the treatment of migraine
AU6337999A (en) Core-extended perylene bisimides
MY133969A (en) Indoloquinazolinones
MXPA05002489A (es) Composiciones para el cuidado personal basadas en alcohol ramificado.
EP1178796A4 (en) AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE
WO2003072053A3 (en) Compounds for treatment of copper overload
BG106002A (en) Process for preparing pesticidal intermediates
MXPA03010498A (es) Proceso para la preparacion de imipenem.
AP1413A (en) Rescorcinol composition.
WO2004060878A3 (en) Inhibitors of phosphatases
CA2270301A1 (en) Hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for their preparation
GB9806409D0 (en) Processes for preparing intermediates
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
IL148161A0 (en) Process for the preparation of 2-cyanopyridines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase